Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kanjinti + Pertuzumab + Vinorelbine vs Docetaxel in First-Line HER2+ Advanced Breast Cancer
NCT03811418Phase 3Withdrawn
- Sponsor
- iOMEDICO
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vinorelbine in HER2-positive breast cancer (2 arms), sponsored by iOMEDICO. Primary endpoint: Patient-reported health-related quality of life (QoL): FACT-B. Planned start Jan 2019; status: withdrawn.
02
Drugs
vinorelbine
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03811418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03811418.